Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner
Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative. Rohto, known for its over-the-counter eye care and skincare products, is among the latest batch…
Full story
Read the full story at South China Morning Post ↗
Continue reading this story on South China Morning Post, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
